Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2018 Feb;6(3):56.
doi: 10.21037/atm.2017.11.36.

Protease activated receptor 4: a backup receptor or a dark horse as a target in antiplatelet therapy?

Xu Han  1 , Marvin T Nieman  1
Affiliations
Editorial

Protease activated receptor 4: a backup receptor or a dark horse as a target in antiplatelet therapy?

Xu Han et al. Ann Transl Med. 2018 Feb.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Platelet activation and current anti-platelet therapeutic strategies. (A) Schematic demonstration of the major signaling pathways involved in platelet adhesion and activation. The primary receptors on the surface of the platelet, GPCRs (PARs, P2Ys, and TP), GPVI and the GPIb-XI-V complex are essential for activating second messengers that lead to shape change and granule secretion; (B) the drugs and experimental compounds that have been developed targeting the key receptors on the surface of platelets are shown. GPCR, G-protein coupled receptor; PAR, protease activated receptor; TP, thromboxane receptor; GPVI, Glycoprotein VI.
Figure 2
Figure 2
Comparison of PAR1 and PAR4 signaling in platelets and the chemical structures of four PAR4 antagonists. (A) PAR1 and PAR4 have overlapping and unique roles in platelet activation. These two GPCRs couple to the same G-proteins, however with distinct kinetics, which has important physiological consequence; (B) chemical structures of the four compounds that have PAR4 antagonism effect. PAR, protease activated receptor; GPCR, G-protein coupled receptor.
See this image and copyright information in PMC

Comment on

References

    1. Wong PC, Seiffert D, Bird JE, et al. Blockade of protease-activated receptor-4 (PAR4) provides robust antithrombotic activity with low bleeding. Sci Transl Med 2017;9. pii: eaaf5294. 10.1126/scitranslmed.aaf5294 - DOI - PubMed
    1. Deng W, Xu Y, Chen W, et al. Platelet clearance via shear-induced unfolding of a membrane mechanoreceptor. Nat Commun 2016;7:12863. 10.1038/ncomms12863 - DOI - PMC - PubMed
    1. Zhang W, Deng W, Zhou L, et al. Identification of a juxtamembrane mechanosensitive domain in the platelet mechanosensor glycoprotein Ib-IX complex. Blood 2015;125:562-9. 10.1182/blood-2014-07-589507 - DOI - PMC - PubMed
    1. Versteeg HH, Heemskerk JW, Levi M, et al. New fundamentals in hemostasis. Physiol Rev 2013;93:327-58. 10.1152/physrev.00016.2011 - DOI - PubMed
    1. Rivera J, Lozano ML, Navarro-Nunez L, et al. Platelet receptors and signaling in the dynamics of thrombus formation. Haematologica 2009;94:700-11. 10.3324/haematol.2008.003178 - DOI - PMC - PubMed

LinkOut - more resources